|
Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
HPO |
|
|
|
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Liver carcinoma
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Our results provide new insight into the mechanisms underlying hyperactivation of the Wnt/β-catenin pathway in HCC, as well the oncogenic ability of TFAP4 to enhance the tumor-forming ability of HCC cells.
|
30026867 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
<b>Rationale:</b> Hepatocellular carcinoma (HCC) is an aggressive malignant solid tumor wherein CDK1/PDK1/β-Catenin is activated, suggesting that inhibition of this pathway may have therapeutic potential.
|
30083256 |
2018 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
HCC is associated with a series of molecular changes, as alternation in glypican-3, P53 expression and Wnt/β-catenin pathway.
|
29429512 |
2018 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity.
|
10435629 |
1999 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Beta-catenin, cyclin D1 and c-Myc, genes related to Wnt pathway, were upregulated in the liver tissues from both 11 weeks and HCC stage of Gnmt-/- mice.
|
19035462 |
2009 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were significantly associated with young age (P=0.019) and moderately/poorly differentiated HCV-related HCC (P=0.015).
|
23583669 |
2013 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
β-Catenin and prothymosin alpha (PTMA) are overexpressed in HCC and other tumors.
|
26517516 |
2015 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 (40%) and TP53 (21%) mutations were mutually exclusive and defined two major groups of HCC characterized by distinct phenotypes.
|
28532995 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were not identified in any HCC-IS, while they were present in 24.1% of C-HCC (p = 0.016).
|
30930222 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 mutations were similarly observed in K19<sup>+</sup> and K19<sup>-</sup> HCC (23% and 19%, respectively), but rare in S-iCCA (3%).
|
31017316 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
A histological examination revealed all HBL cases involving tumors without detectable CTNNB1 gene alterations to show high expression of beta-catenin, thus indicating the accumulation of beta-catenin to be a common event in malignant PLTs, including HBL and hepatocellular carcinoma.
|
16465411 |
2006 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A majority of human colorectal tumors and hepatomas are known to possess a constitutively active canonical Wnt/beta-catenin/TCF signaling pathway, also express CR-1.
|
17291450 |
2007 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A number of recently published NGS studies on HCCs have not only confirmed previously known mutations in CTNNB1 and TP53 in HCC, but also identified novel genetic alterations in HCC including mutations in genes involved in epigenetic regulation.
|
23063663 |
2013 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A series of nine CC, 15 HCC-CC and three separated HCC and CC lesions ('collision tumors') were screened for loss of heterozygosity (LOH) using 400 microsatellite markers and for p53 and beta-catenin mutations.
|
15288479 |
2004 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
A total of 89 HCC samples were analyzed in this study to determine how alterations in the Wnt signaling pathway associate with the carcinogenesis of HCC. beta-catenin immunohistochemistry showed positive nuclear staining in 24 (27.0%) of the 89 HCC samples, indicating the existence of alterations in the Wnt signaling pathway in those 24 HCC samples.
|
15067328 |
2004 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A β‑catenin mutant and β‑catenin wild‑type HCC models were treated once daily with i) 10 mg/kg sorafenib, ii) 15 mg/kg refametinib (or 25 mg/kg selumetinib), or iii) sorafenib/refametinib.
|
30747223 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of β-catenin and Yes-associated protein (YAP) signaling pathways has been associated with hepatocellular carcinoma (HCC) progression.
|
30041665 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Aberrant expression of the Wnt-beta-catenin pathway and enzymes for DNA replication also could contribute to the pathogenesis of HCC.
|
11752456 |
2001 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Abnormal nuclear expression of beta-catenin was observed in 11 of 36 cases of HCCs (30.6%), but not in cirrhotic nodules.
|
18171349 |
2008 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
About half the HCCs with AXIN1 or AXIN2 mutations showed beta-catenin accumulation in the nucleus, cytoplasm or membrane.
|
12101426 |
2002 |